Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
Dow
Johnson and Johnson
McKesson

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020823

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 020823 describes EXELON, which is a drug marketed by Novartis and is included in three NDAs. It is available from two suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EXELON profile page.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for 020823
Tradename:EXELON
Applicant:Novartis
Ingredient:rivastigmine tartrate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020823
Mechanism of ActionCholinesterase Inhibitors
Suppliers and Packaging for NDA: 020823
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EXELON rivastigmine tartrate CAPSULE;ORAL 020823 NDA Novartis Pharmaceuticals Corporation 0078-0323 0078-0323-08 500 CAPSULE in 1 BOTTLE (0078-0323-08)
EXELON rivastigmine tartrate CAPSULE;ORAL 020823 NDA Novartis Pharmaceuticals Corporation 0078-0323 0078-0323-15 30 CAPSULE in 1 BLISTER PACK (0078-0323-15)
Paragraph IV (Patent) Challenges for 020823
Tradename Dosage Ingredient NDA Submissiondate
EXELON CAPSULE;ORAL rivastigmine tartrate 020823 2004-04-21

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:Apr 21, 2000TE:RLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 3MG BASE
Approval Date:Apr 21, 2000TE:RLD:Yes

Profile for product number 005

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 4.5MG BASE
Approval Date:Apr 21, 2000TE:RLD:Yes

Expired US Patents for NDA 020823

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000   Start Trial   Start Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000   Start Trial   Start Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Baxter
McKinsey
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.